A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Bexarotene (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 27 Sep 2019 Planned End Date changed from 23 Sep 2019 to 31 Aug 2020.
- 27 Sep 2019 Planned primary completion date changed from 23 Sep 2019 to 31 Aug 2020.
- 11 Jun 2019 Status changed from suspended to recruiting.